Advertisement
Canada markets open in 6 hours 11 minutes
  • S&P/TSX

    21,639.10
    -59.00 (-0.27%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • DOW

    38,589.16
    -57.94 (-0.15%)
     
  • CAD/USD

    0.7281
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    78.27
    -0.18 (-0.23%)
     
  • Bitcoin CAD

    90,675.98
    -357.33 (-0.39%)
     
  • CMC Crypto 200

    1,394.37
    +6.21 (+0.45%)
     
  • GOLD FUTURES

    2,333.40
    -15.70 (-0.67%)
     
  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     
  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     
  • NASDAQ futures

    19,714.00
    +28.50 (+0.14%)
     
  • VOLATILITY

    12.66
    0.00 (0.00%)
     
  • FTSE

    8,165.79
    +18.93 (+0.23%)
     
  • NIKKEI 225

    38,102.44
    -712.12 (-1.83%)
     
  • CAD/EUR

    0.6802
    +0.0004 (+0.06%)
     

Sutro Biopharma Third Quarter 2022 Earnings: Misses Expectations

Sutro Biopharma (NASDAQ:STRO) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$25.1m (up 195% from 3Q 2021).

  • Net loss: US$19.5m (loss narrowed by 37% from 3Q 2021).

  • US$0.37 loss per share (improved from US$0.67 loss in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sutro Biopharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Sutro Biopharma you should be aware of, and 1 of them is a bit concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here